Compare Revolution Medicines Inc. Common Stock (RVMD) vs StoneX Group Inc. Common Stock (SNEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revolution Medicines Inc. Common Stock vs StoneX Group Inc. Common Stock — how do they compare? Revolution Medicines Inc. Common Stock trades at $190 (market cap $41.53B), while StoneX Group Inc. Common Stock trades at $59.51 (market cap $7.23B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 5.7× StoneX Group Inc. Common Stock's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, StoneX Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 2 Days and StoneX Group Inc. Common Stock for 0 Days on average.
| RVMD | SNEX | |
|---|---|---|
Market Cap | $41.53B | $7.23B |
Volume | 2,462,910 | 869,596 |
Sector | Health | Financials |
52-Week High | $221.15 | $92.67 |
52-Week Low | $49.56 | $37.20 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $38.24B | $28.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →About StoneX Group Inc. Common Stock
StoneX Group Inc. is a financial services firm providing trading, clearing, execution, and cross-border payment services to institutional, commercial, and self-directed retail clients across global markets.
Read more on SNEX →
